邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

《脊柱关节炎靶向药物治疗专家共识》要点解读

杨晓曦,  田新平,  李梦涛,  冷晓梅,  赵岩,  曾小峰

downloadPDF
文章导航 > 协和医学杂志  > 优先出版
杨晓曦, 田新平, 李梦涛, 冷晓梅, 赵岩, 曾小峰. 《脊柱关节炎靶向药物治疗专家共识》要点解读[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2023-0391
引用本文: 杨晓曦, 田新平, 李梦涛, 冷晓梅, 赵岩, 曾小峰. 《脊柱关节炎靶向药物治疗专家共识》要点解读[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2023-0391
shu
YANG Xiaoxi, TIAN Xinping, LI Mengtao, LENG Xiaomei, ZHAO Yan, ZENG Xiaofeng. Interpretation on the Consensus on Targeted Drug Therapy for Spondyloarthritis[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2023-0391
Citation: YANG Xiaoxi, TIAN Xinping, LI Mengtao, LENG Xiaomei, ZHAO Yan, ZENG Xiaofeng. Interpretation on the Consensus on Targeted Drug Therapy for Spondyloarthritis[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2023-0391
shu

《脊柱关节炎靶向药物治疗专家共识》要点解读

doi: 10.12290/xhyxzz.2023-0391

  • 1 中国医学科学院北京协和医院 风湿免疫科 国家皮肤与免疫疾病临床医学研究中心 风湿免疫病学教育部重点实验室, 北京 100730;

  • 2 中国医学科学院北京协和医院 疑难重症及罕见病国家重点实验室, 北京 100730

基金项目: 

中国医学科学院医学与健康科技创新工程项目（2021-I2M-1-005）；中央高水平医院临床科研专项（2022-PUMCH-B-013）

详细信息
    通讯作者:

    曾小峰,E-mail:zengxfpumc@163.com

  • 中图分类号: R593.22；R593.22；R971+.1

Interpretation on the Consensus on Targeted Drug Therapy for Spondyloarthritis

  • 1 Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences&Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science&Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China;

  • 2 State Key Laboratory of Complex Severe and Rare Diseases, Chinese Academy of Medical Sciences&Peking Union Medical College, Beijing 100730, China

Funds: 

CAMS Innovation Fund for Medical Sciences (2021-I2M-1-005); National High Level Hospital Clinical Research Funding (2022-PUMCH-B-013)

    摘要
  • 摘要: 脊柱关节炎(spondyloarthritis，SpA)是一组以中轴骨和/或外周关节受累为主的慢性炎症性、致残性风湿免疫病，严重影响患者的生活质量和身体功能。随着靶向药物的临床应用越来越多，精准且规范应用成为目前关注的重点。遵循共识制订的国际规范，国家皮肤与免疫疾病临床医学研究中心制定了我国首部《脊柱关节炎靶向药物治疗专家共识》，该共识对13个靶向药物应用过程中的重点问题作出推荐，涵盖了靶向药物治疗SpA的原则、适用人群、用药前筛查、用药时机、药物选择和转换、合并用药、不良反应监测等，并对特殊人群的用药注意事项提出建议，对临床实践具有重要指导意义。
    Abstract: Spondyloarthritis (SpA) is a group of chronic inflammatory diseases which predominantly involve spine and/or peripheral joints. SpA can be disabling and seriously affect the quality of life and function of patients. With the increasing clinical use of targeted drug therapy, precise and standardized use becomes the focus. China's first Consensus on Targeted Drug Therapy for Spondyloarthritis was developed by National Clinical Research Center for Dermatologic and Immunologic Diseases using international norms for consensus development. The consensus addresses 13 important clinical questions, ranging from principles, patient eligibility, pre-treatment screening, treatment initiation, drug selection and switch, comedication, to adverse event monitoring of targeted drug therapy in SpA, and recommends treatment for specific patients, playing a key role in guiding clinical practices.
    • HTML全文
    • 参考文献(79)
  • [1] Ng SC, Liao Z, Yu DT, et al. Epidemiology of spondyloarthritis in the People's Republic of China:review of the literature and commentary[J]. Semin Arthritis Rheum, 2007, 37:39-47.
    [2] 国家皮肤与免疫疾病临床医学研究中心(北京协和医院), 中国医师协会风湿免疫专科医师分会, 中国康复医学会风湿免疫专业委员会, 等. 脊柱关节炎靶向药物治疗专家共识[J]. 中华内科杂志, 2023, 62:606-618.
    [3] Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis:2022 update[J]. Ann Rheum Dis, 2023, 82:19-34.
    [4] Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis[J]. Arthritis Rheumatol, 2019, 71:1599-1613.
    [5] van der Heijde D, Baraf HS, Ramos-Remus C, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis:results of a fifty-two-week, randomized, controlled study[J]. Arthritis Rheum, 2005, 52:1205-1215.
    [6] Wanders A, van der Heijde D, Landewé R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis:a randomized clinical trial[J]. Arthritis Rheum, 2005, 52:1756-1765.
    [7] Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study[J]. Arthritis Rheum, 1996, 39:2004-2012.
    [8] Gonzalez-Lopez L, Garcia-Gonzalez A, Vazquez-Del-Mercado M, et al. Efficacy of methotrexate in ankylosing spondylitis:a randomized, double blind, placebo controlled trial[J]. J Rheumatol, 2004, 31:1568-1574.
    [9] Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies:2019 update[J]. Ann Rheum Dis, 2020, 79:700-712.
    [10] 中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物制剂治疗指南(2021)[J].中华皮肤科杂志, 2021, 54:1033-1047.
    [11] Machado P, Landewé R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS):defining cut-off values for disease activity states and improvement scores[J]. Ann Rheum Dis, 2011, 70:47-53.
    [12] Schett G, Lories RJ, D'Agostino MA, et al. Enthesitis:from pathophysiology to treatment[J]. Nat Rev Rheumatol, 2017, 13:731-741.
    [13] Rocha FAC, Pinto ACMD, Lopes JR, et al. Tumor necrosis factor inhibitors prevent structural damage in hips in ankylosing spondylitis-time to reconsider treatment guidelines? A case series and review of literature[J]. Clin Rheumatol, 2021, 40:1881-1887.
    [14] Sepriano A, Kerschbaumer A, Bergstra SA, et al. Safety of synthetic and biological DMARDs:a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis[J].Ann Rheum Dis, 2023, 82:107-118.
    [15] Liu J, Zhang S, Wang Q, et al. Seroepidemiology of hepatitis B virus infection in 2 million men aged 21-49 years in rural China:a population-based, cross-sectional study[J]. Lancet Infect Dis, 2016, 16:80-86.
    [16] Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy[J].Gastroenterology, 2015, 148:221-244.
    [17] Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy[J].Gastroenterology, 2015, 148:215-219.
    [18] Chen YM, Huang WN, Wu YD, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib:a real-world study[J].Ann Rheum Dis, 2018, 77:780-782.
    [19] Akiyama S, Cotter TG, Sakuraba A. Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics[J]. World J Gastroenterol, 2021, 27:2312-2324.
    [20] 黄安芳, 罗妍, 赵毅, 等.风湿病患者合并潜伏性结核感染的分析[J].中华内科杂志, 2016, 55:307-310.
    [21] Minozzi S, Bonovas S, Lytras T, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis:a systematic review and meta-analysis[J]. Expert Opin Drug Saf, 2016, 15:11-34.
    [22] Alves C, Penedones A, Mendes D, et al.The Risk of Infections Associated With JAK Inhibitors in Rheumatoid Arthritis:A Systematic Review and Network Meta-analysis[J].J Clin Rheumatol, 2022, 28:e407-e414.
    [23] Thatiparthi A, Martin A, Liu J, et al. Biologic Treatment Algorithms for Moderate-toSevere Psoriasis with Comorbid Conditions and Special Populations:A Review[J]. Am J Clin Dermatol, 2021, 22:425-442.
    [24] Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis:results of a double-blind, randomized, placebo-controlled trial[J]. Arthritis Rheum, 2005, 52:3279-3289.
    [25] Kavanaugh A, McInnes IB, Krueger GG, et al.Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab:findings through 2 years of a phase Ⅲ, multicenter, randomized, double-blind, placebo-controlled trial[J]. Arthritis Care Res (Hoboken), 2013, 65:1666-1673.
    [26] Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis:24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)[J]. Ann Rheum Dis, 2014, 73:48-55.
    [27] Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis:results of the IMPACT 2 trial[J]. Ann Rheum Dis, 2005, 64:1150-1157.
    [28] McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2):a randomised, doubleblind, placebo-controlled, phase 3 trial[J]. Lancet, 2015, 386:1137-1146.
    [29] Nash P, Coates LC, Kivitz AJ, et al. Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis:Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study[J]. Rheumatol Ther, 2020, 7:553-580.
    [30] McInnes IB, Kato K, Magrey M, et al. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy:56-week data from the phase 3 SELECTPsA 1 study[J]. RMD Open, 2021, 7:e001838.
    [31] Mease PJ, Lertratanakul A, Papp KA, et al.Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics:56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study[J]. Rheumatol Ther, 2021, 8:903-919.
    [32] Kavanaugh A, Puig L, Gottlieb AB, et al. Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis:Results From a Randomized, Placebo-Controlled Phase Ⅲ Trial[J]. Arthritis Care Res (Hoboken), 2015, 67:1739-1749.
    [33] Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1):a double-blind, randomised, placebo-controlled phase 3 trial[J]. Lancet, 2020, 395:1115-1125.
    [34] Mease PJ, Gottlieb AB, van der Heijde D, et al. Efficacy and safety of abatacept, a Tcell modulator, in a randomised, double-blind, placebo-controlled, phase Ⅲ study in psoriatic arthritis[J]. Ann Rheum Dis, 2017, 76:1550-1558.
    [35] Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement:a phase Ⅲ, randomised, controlled trial (PALACE 3)[J]. Ann Rheum Dis, 2016, 75:1065-1073.
    [36] McInnes IB, Behrens F, Mease PJ, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED):a double-blind, parallel-group, randomised, activecontrolled, phase 3b trial[J]. Lancet, 2020, 395:1496-1505.
    [37] Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis:24-week results of a randomised, open-label, blinded-assessor trial[J]. Ann Rheum Dis, 2020, 79:123-131.
    [38] Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors:results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial[J]. Lancet, 2017, 389:2317-2327.
    [39] Reich K, Sullivan J, Arenberger P, et al. Secukinumab shows high and sustained efficacy in nail psoriasis:2.5-year results from the randomized placebo-controlled TRANSFIGURE study[J]. Br J Dermatol, 2021, 184:425-436.
    [40] Coates LC, Wallman JK, McGonagle D, et al. Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis:pooled analysis of two phase 3 studies[J]. Arthritis Res Ther, 2019, 21:266.
    [41] Vieira-Sousa E, Alves P, Rodrigues AM, et al. GO-DACT:a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis[J]. Ann Rheum Dis, 2020, 79:490-498.
    [42] Gladman DD, Orbai AM, Klitz U, et al. Ixekizumab and complete resolution of enthesitis and dactylitis:integrated analysis of two phase 3 randomized trials in psoriatic arthritis[J]. Arthritis Res Ther, 2019, 21:38.
    [43] McGonagle D, McInnes IB, Deodhar A, et al. Resolution of enthesitis by guselkumab and relationships to disease burden:1-year results of two phase 3 psoriatic arthritis studies[J]. Rheumatology (Oxford), 2021, 60:5337-5350.
    [44] Singh JA, Guyatt G, Ogdie A, et al. Special Article:2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis[J]. Arthritis Care Res (Hoboken), 2019, 71:2-29.
    [45] Robinson PC, van der Linden S, Khan MA, et al. Axial spondyloarthritis:concept, construct, classification and implications for therapy[J]. Nat Rev Rheumatol, 2021, 17:109-118.
    [46] Braun J, Baraliakos X, Listing J, et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept[J].Arthritis Rheum, 2005, 52:2447-2451.
    [47] van Denderen JC, Visman IM, Nurmohamed MT, et al. Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis[J]. J Rheumatol, 2014, 41:1843-1848.
    [48] van der Horst-Bruinsma I, van Bentum R, Verbraak FD, et al. The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis:48-week interim results from C-VIEW[J]. RMD Open, 2020, 6:e001161.
    [49] van Bentum RE, Heslinga SC, Nurmohamed MT, et al. Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab-The GO-EASY Study[J].J Rheumatol, 2019, 46:153-159.
    [50] Lindström U, Bengtsson K, Olofsson T, et al. Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care:does the choice of biological therapy matter?[J] Ann Rheum Dis, 2021, 80:1445-1452.
    [51] Sandborn WJ, Hanauer SB, Katz S, et al.Etanercept for active Crohn's disease:a randomized, double-blind, placebo-controlled trial[J]. Gastroenterology, 2001, 121:1088-1094.
    [52] Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease:the ACCENT I randomised trial[J].Lancet, 2002, 359:1541-1549.
    [53] Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease:results of the CLASSIC Ⅱ trial[J].Gut, 2007, 56:1232-1239.
    [54] Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease[J]. N Engl J Med, 2007, 357:228-238.
    [55] Adedokun OJ, Xu Z, Marano CW, et al. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis:Results from Phase 2/3 PURSUIT Induction and Maintenance Studies[J]. J Crohns Colitis, 2017, 11:35-46.
    [56] Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease:unexpected results of a randomised, double-blind placebo-controlled trial[J]. Gut, 2012, 61:1693-1700.
    [57] Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of ankylosing spondylitis:a phase Ⅲ, randomised, double-blind, placebo-controlled study[J]. Ann Rheum Dis, 2021, 80:1004-1013.
    [58] van der Heijde D, Song IH, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1):a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial[J]. Lancet, 2019, 394:2108-2117.
    [59] Deodhar A, Van den Bosch F, Poddubnyy D, et al. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2):a randomised, doubleblind, placebo-controlled, phase 3 trial[J]. Lancet, 2022, 400:369-379.
    [60] Mulleman D, Lauféron F, Wendling D, et al. Infliximab in ankylosing spondylitis:alone or in combination with methotrexate? A pharmacokinetic comparative study[J].Arthritis Res Ther, 2011, 13:R82.
    [61] Nissen MJ, Ciurea A, Bernhard J, et al. The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis[J]. Arthritis Rheumatol, 2016, 68:2141-2150.
    [62] Smolen JS, Schöls M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target:2017 update of recommendations by an international task force[J].Ann Rheum Dis, 2018, 77:3-17.
    [63] van der Heijde D, Lie E, Kvien TK, et al. ASDAS, a highly discriminatory ASASendorsed disease activity score in patients with ankylosing spondylitis[J]. Ann Rheum Dis, 2009, 68:1811-1818.
    [64] Ramiro S, van der Heijde D, van Tubergen A, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis:12-year longitudinal data from the OASIS cohort[J]. Ann Rheum Dis, 2014, 73:1455-1461.
    [65] Navarro-Compán V, Plasencia-Rodríguez C, de Miguel E, et al. Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis:a systematic literature review[J]. Rheumatology (Oxford), 2016, 55:1188-1194.
    [66] Saoussen M, Yasmine M, Lilia N, et al. Tapering biologics in axial spondyloarthritis:A systematic literature review[J]. Int Immunopharmacol, 2022, 112:109256.
    [67] Molto A, López-Medina C, Van den Bosch FE, et al. Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis:results of the open-label, pragmatic, clusterrandomised TICOSPA trial[J]. Ann Rheum Dis, 2021, 80:1436-1444.
    [68] 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家建议组. 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家共识[J]. 中华风湿病学杂志, 2013, 17:508-512.
    [69] 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南(2022年 版)[J].中华传染病杂志, 2023, 41:3-28.
    [70] Sinagra E, Perricone G, Romano C, et al. Heart failure and anti tumor necrosis factoralpha in systemic chronic inflammatory diseases[J].Eur J Intern Med, 2013, 24:385-392.
    [71] Sun WT, He YH, Dong MM, et al. The comparative safety of biological treatment in patients with axial spondylarthritis:a meta-analysis of randomized controlled trials with placebo[J]. Eur Rev Med Pharmacol Sci, 2020, 24:9824-9836.
    [72] Xie W, Xiao S, Huang Y, et al. A meta-analysis of biologic therapies on risk of new or recurrent cancer in patients with rheumatoid arthritis and a prior malignancy[J]. Rheumatology (Oxford), 2021, 60:2495.
    [73] D'Angelo S, Carriero A, Gilio M, et al. Safety of treatment options for spondyloarthritis:a narrative review[J]. Expert Opin Drug Saf, 2018, 17:475-486.
    [74] Winthrop KL, Cohen SB. Oral surveillance and JAK inhibitor safety:the theory of relativity[J]. Nat Rev Rheumatol, 2022, 18:301-304.
    [75] Chang CC, Chang YS, Chen WS, et al. Effects of annual influenza vaccination on morbidity and mortality in patients with Systemic Lupus Erythematosus:A Nationwide Cohort Study[J]. Sci Rep, 2016, 6:37817.
    [76] Kobashigawa T, Nakajima A, Taniguchi A, et al. Vaccination against seasonal influenza is effective in Japanese patients with rheumatoid arthritis enrolled in a large observational cohort[J]. Scand J Rheumatol, 2013, 42:445-450.
    [77] Goodman SM, Springer BD, Chen AF, et al. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty[J]. Arthritis Care Res (Hoboken), 2022, 74:1399-1408.
    [78] Clowse MEB, Scheuerle AE, Chambers C, et al. Pregnancy Outcomes After Exposure to Certolizumab Pegol:Updated Results From a Pharmacovigilance Safety Database[J]. Arthritis Rheumatol, 2018, 70:1399-1407.
    [79] Flint J, Panchal S, Hurrell A, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I:standard and biologic disease modifying anti-rheumatic drugs and corticosteroids[J]. Rheumatology (Oxford), 2016, 55:1693-1697.
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  25
  • HTML全文浏览量:  2
  • PDF下载量:  11
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-08-23
  • 网络出版日期:  2023-10-31

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！